Aligos Therapeutics (NASDAQ:ALGS) Given Buy Rating at HC Wainwright

Aligos Therapeutics (NASDAQ:ALGS)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $70.00 target price on the stock.

Aligos Therapeutics Price Performance

Aligos Therapeutics stock opened at $9.12 on Monday. The firm has a 50-day moving average of $19.21 and a 200-day moving average of $20.29. The company has a market cap of $55.76 million, a price-to-earnings ratio of -0.68 and a beta of 2.52. Aligos Therapeutics has a one year low of $6.76 and a one year high of $46.80.

Aligos Therapeutics (NASDAQ:ALGS) last posted its quarterly earnings results on Monday, March 10th. The company reported ($13.08) earnings per share for the quarter, missing the consensus estimate of ($2.63) by ($10.45). The company had revenue of $0.63 million for the quarter, compared to analyst estimates of $0.43 million. Aligos Therapeutics had a negative return on equity of 114.34% and a negative net margin of 1,283.19%. During the same period last year, the firm earned ($5.50) EPS. As a group, sell-side analysts expect that Aligos Therapeutics will post -10.36 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ALGS. Tower Research Capital LLC TRC raised its holdings in shares of Aligos Therapeutics by 2,073.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 652 shares of the company’s stock valued at $26,000 after purchasing an additional 622 shares during the period. AlphaMark Advisors LLC increased its position in Aligos Therapeutics by 1,000.0% during the fourth quarter. AlphaMark Advisors LLC now owns 1,100 shares of the company’s stock worth $44,000 after buying an additional 1,000 shares during the last quarter. Golden State Wealth Management LLC acquired a new position in Aligos Therapeutics during the fourth quarter worth approximately $107,000. Northern Trust Corp bought a new stake in Aligos Therapeutics in the fourth quarter valued at approximately $205,000. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Aligos Therapeutics by 19.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 14,286 shares of the company’s stock valued at $569,000 after buying an additional 2,306 shares during the last quarter. Institutional investors own 60.43% of the company’s stock.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).